Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the US

被引:78
作者
Parsons, Jeffrey T. [1 ,2 ,3 ]
Rendina, H. Jonathon [1 ]
Whitfield, Thomas H. F. [1 ,2 ]
Grov, Christian [1 ,4 ]
机构
[1] CUNY Hunter Coll, Ctr HIV AIDS Educ Studies & Training, New York, NY 10021 USA
[2] CUNY, Grad Ctr, Hlth Psychol & Clin Sci Doctoral Program, New York, NY USA
[3] CUNY Hunter Coll, Dept Psychol, 695 Pk Ave, New York, NY 10065 USA
[4] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA
关键词
Gay and bisexual men; Pre-exposure prophylaxis (PrEP); Long-acting injectable PrEP; HIV prevention; Biomedical strategies; ANTIRETROVIRAL PROPHYLAXIS; CONDOM USE; SEX; INFECTION; ADHERENCE; RISK; ACCEPTABILITY; INTERMITTENT; PREVENTION; CHALLENGES;
D O I
10.1007/s10461-016-1370-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP among gay and bisexual men (GBM). We surveyed a national U.S. sample of 1071 GBM about forms of PrEP. LAI PrEP was found to be acceptable among 43.2 % of men when injected monthly compared with 53.6 % of men when injected every 3 months. When asked to choose between forms of PrEP, 46.0 % preferred LAI, 14.3 % oral, 21.7 % whichever was most effective, 10.1 % had no preference, and 7.8 % would not take PrEP. There were no differences in PrEP preferences by race/ethnicity, income, region of residence, or relationship status. Those unwilling to take PrEP were significantly older than those who preferred LAI PrEP and those who would take either. Those who preferred the most effective form were younger, had less education, and reported more recent club drug use. Those who reported condomless anal sex and those who thought they were good PrEP candidates were more willing to take PrEP. Long-term health and side effects were of the greatest concern for both LAI and oral PrEP. The availability of LAI PrEP has the potential to increase uptake among GBM. The results of ongoing clinical trials of LAI PrEP will need to demonstrate similar or greater efficacy as daily Truvada for uptake to be maximized.
引用
收藏
页码:1390 / 1399
页数:10
相关论文
共 50 条
  • [1] Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey
    Aghaizu, Adamma
    Mercey, Danielle
    Copas, Andrew
    Johnson, Anne M.
    Hart, Graham
    Nardone, Anthony
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 (03) : 207 - 211
  • [2] Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
    Amico, K. Rivet
    Stirratt, Michael J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 : S55 - S60
  • [3] A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
    Andrews, Chasity D.
    Yueh, Yun Lan
    Spreen, William R.
    St Bernard, Leslie
    Boente-Carrera, Mar
    Rodriguez, Kristina
    Gettie, Agegnehu
    Russell-Lodrigue, Kasi
    Blanchard, James
    Ford, Susan
    Mohri, Hiroshi
    Cheng-Mayer, Cecilia
    Hong, Zhi
    Ho, David D.
    Markowitz, Martin
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (270)
  • [4] Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
    Andrews, Chasity D.
    Spreen, William R.
    Mohri, Hiroshi
    Moss, Lee
    Ford, Susan
    Gettie, Agegnehu
    Russell-Lodrigue, Kasi
    Bohm, Rudolf P.
    Cheng-Mayer, Cecilia
    Hong, Zhi
    Markowitz, Martin
    Ho, David D.
    [J]. SCIENCE, 2014, 343 (6175) : 1151 - 1154
  • [5] [Anonymous], 2013, HIV Surveillance Supplemental Report, V18
  • [6] [Anonymous], 2012, HIV Surveillance Supplemental Report, V17
  • [7] [Anonymous], HIV SURV EP HIV INF
  • [8] [Anonymous], 2014, STUDY EVALUATE SAFET
  • [9] [Anonymous], 2015, C RETR OPP INF
  • [10] Ayala George, 2013, J Sex Transm Dis, V2013, P953123, DOI 10.1155/2013/953123